Psyrin raises $1 million to advance its pioneering approach to mental health assessment using voice biomarkers

Psyrin, a London-based mental health tech startup, recently secured $1 million in pre-seed funding led by 2048 Ventures with participation from Concept Ventures and Space Cadet Ventures. This funding will enable Psyrin to advance its pioneering approach to mental health assessment using voice biomarkers, setting the stage for a more objective and data-driven approach in a field traditionally reliant on subjective evaluations. Psyrin’s flagship product, Simon AI, uses voice patterns to help identify potential signs of neurodivergence, with a focus on ADHD and autism. By analysing over 200 unique voice markers, Simon AI provides insights that go beyond conventional diagnostic labels, offering users a detailed understanding of their mental health.

The mental health industry faces significant infrastructure challenges, especially in terms of timely access to assessments. Traditional methods often require extensive interviews and are limited by a shortage of trained professionals, creating lengthy waiting times. In the UK, for instance, wait times for mental health assessments can exceed 500 weeks. Psyrin aims to alleviate these bottlenecks by introducing technology that can provide rapid, reliable insights through voice analysis, giving clinicians a tool that enhances efficiency without sacrificing accuracy.

Simon AI’s voice biomarker technology operates by examining a wide array of vocal characteristics, such as tone, loudness, sentence complexity, and other nuanced markers. This approach brings a level of precision to mental health assessments that has not been widely available before. By shifting the focus from traditional diagnostic categories to measurable traits, Psyrin introduces a new paradigm in mental health care, enabling individuals to gain insights into their neurodivergent tendencies without waiting for formal diagnosis processes.

The founders of Psyrin, Dr. Edwin Wong, Dr. Julianna Olah, and Dr. Raheem Chaudhry, bring a diverse background in psychiatry, systems neuroscience, and machine learning. This unique combination of expertise positions Psyrin at the forefront of mental health technology, as the team is committed to transforming the way mental health is assessed and understood. Their goal is to move beyond simple diagnosis, enabling personalised mental health insights that empower users to better understand their own brain functions.

Concept Ventures, one of the investors in Psyrin, is enthusiastic about the potential impact of Simon AI. “Psyrin’s use of voice biomarkers introduces an objective dimension to mental health assessment, transforming a field that has traditionally relied on subjective observations,” notes Concept Ventures. The firm believes that Psyrin’s technology will play a vital role in shifting mental health care towards preventive and personalised treatment models, especially as the market for digital health solutions continues to expand.

Voice biomarkers are at the heart of Psyrin’s innovation. These biomarkers, which are measurable indicators of biological states, allow Simon AI to assess neurodivergence traits through voice analysis. The technology’s precision stems from its ability to analyse both intuitive aspects, like tone and volume, and complex elements derived from mathematical transformations of voice. This multifaceted analysis enables Simon AI to provide a comprehensive view of an individual’s mental health, enhancing the accuracy of potential neurodivergence identification.

The use of voice as a primary tool for mental health assessment is timely, as society becomes more comfortable interacting with technology through voice. The rise of voice assistants and AI wearables has made voice a natural modality for assessing emotional and mental states. By extracting mental health indicators from voice, Psyrin is capitalising on this trend, offering a non-intrusive and accessible method for mental health tracking and assessment.

Simon AI marks only the beginning of Psyrin’s journey. The company’s vision extends beyond neurodivergence assessment to broader mental health applications, including early intervention for serious mental illnesses. By providing clinicians with tools that facilitate faster assessments and continuous monitoring, Psyrin aims to redefine preventive care, allowing for interventions before conditions worsen.

In summary, Psyrin’s recent funding and the launch of Simon AI highlight a transformative step in mental health assessment. With voice biomarkers at its core, Psyrin offers a more precise and accessible alternative to traditional mental health evaluations. Supported by investors such as Concept Ventures and 2048 Ventures, Psyrin is poised to make a significant impact on mental health care, promoting a future where individuals can track and understand their mental health as easily as they monitor physical health.

‍